Table 3 PDCs under phase III or phase II development
Name | Phase | Target antigen | Payload | Refs |
|---|---|---|---|---|
GRN1005 | 3 | LRP-1 | Paclitaxel | [161] |
AEZS-108 | 3 | LHRH receptor | DOX | [162] |
EP-100 | 2 | LHRH receptor | Cationic lytic peptides | [163] |
BT1718 | 1/2 | MT1-MMP | Mertansine (DM1) | [159] |
BT5528 | 1/2 | EphA2 | MMAE | [123] |
BT8009 | 1/2 | Nectin-4 | MMAE | [124] |
CBX-12 | 1/2 | Topoisomerase I (TOP1) | Exatecan (DX-8951f) | [164] |
L-377202 | 1/2 | Prostate-specific antigen (PSA) | DOX | [165] |
PEN-221 | 1/2 | Somatostatin receptor 2 (SSTR2) | Mertansine(DM1) | [166] |